Astrazeneca’s Stock is Outperforming the Company
Pharmaceutical company AstraZeneca (NYSE: AZN) is in a unique situation currently. The stock is performing much better than the company. What do I mean by that? The stock price is growing much faster than the company’s earnings or sales.
If we look at the daily chart, you can see that the stock price has been trending higher over the last nine months. The upward trend actually goes back to the end of 2016, but I wanted to show you the trend channel that has formed on the stock over the last nine months.
The stock has just bounced off of the lower rail of the channel and the stochastic readings have just made a bullish crossover and look to be moving out of oversold territory. The last time we saw this same scenario was in mid-October and the stock jumped from below $37 to over $41.50.
If you look back over the last two years, the stock has gained 57.3% while the S&P is up 17.5% over this same time period. If we look at Investor’s Business Daily’s relative strength rating, the stock scores a 90. This means that Astrazeneca’s stock has appreciated better than 90% of all publicly traded stocks over the past year.
In the meantime, the company has seen earnings decline by an average of 5% per year over the last three years and sales have declined at a 5% rate over the same period. In the most recent quarterly report, earnings dropped by 37% and sales dropped by 14%.
This is a unique scenario and you wouldn’t expect it to go on very long. Either the fundamentals will catch up with the stock price, or the stock price will start falling to catch up to the earnings and sales on the downside.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
Momentum Indicator for AZN turns positive, indicating new upward trend
AZN saw its Momentum Indicator move above the 0 level on August 18, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned positive. In of the 78 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AZN's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on August 18, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in of 336 cases, the price rose further within the following month. The odds of a continued upward trend are .
AZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AZN entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.233) is normal, around the industry mean (19.422). P/E Ratio (25.398) is within average values for comparable stocks, (33.317). Projected Growth (PEG Ratio) (1.465) is also within normal values, averaging (11.305). Dividend Yield (0.019) settles around the average of (0.027) among similar stocks. P/S Ratio (4.320) is also within normal values, averaging (4.270).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AZN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement